Exploring "Curable Hematological Diseases": The First Immersive Lymphoma Light and Shadow Science Exhibition Opened in Shanghai
September 15th is the 20th World Lymphoma Awareness Day. This special patient group has become increasingly familiar to the public in recent years, but what are the classifications of lymphoma? Is it a curable disease? How can early diagnosis and treatment be achieved?
In order to popularize knowledge about related diseases, the first immersive lymphoma themed light and shadow science popularization exhibition in China recently opened in Shanghai. The organizer stated that this exhibition takes the audience into the micro world of the human body, exploring the mysteries of life and the "past and present" of lymphoma diagnosis and treatment, aiming to convey the message that "lymphoma can be cured through standardized diagnosis and treatment", and hoping to showcase the spirit of doctors and patients working together to fight against lymphoma to society. This science popularization exhibition is jointly organized by Lymphoma Home and Roche Pharmaceuticals China.
Immersive Journey Across the "Lymphoma Planet"
Lymphoma, known as "thousand face tumor", is one of the most common hematological malignancies in China. The incidence rate of malignancies ranks eighth in China, with about 100000 new lymphoma patients every year. Among them, it can be divided into Hodgkin's lymphoma and non Hodgkin's lymphoma according to the pathological type. Among non Hodgkin's lymphoma, diffuse large B-cell lymphoma and follicular lymphoma are the most common.
![Exploring "Curable Hematological Diseases": The First Immersive Lymphoma Light and Shadow Science Exhibition Opened in Shanghai](https://a5qu.com/upload/images/8291196850f40c2fd471547c1437754a.jpeg)
Diffuse large B-cell lymphoma is the most aggressive malignant lymphoma with the highest incidence rate, accounting for about 35% to 40% of non Hodgkin's lymphoma. Compared with other lymphoid system tumors, the prognosis is poor, and about 40% to 50% of patients still have the risk of recurrence after first-line treatment. Follicular lymphoma is also one of the B-cell lymphoma with high incidence rate in China, which has the characteristics of recurrent and refractory disease. Liang Aibin, Vice Dean of Tongji Hospital affiliated with Tongji University and Director of the Institute of Hematology at Tongji University, introduced that lymphoma can occur in various organs and tissues throughout the body. There are actually many early symptoms, but the most common ones are weight loss, fever, night sweats, and skin itching.
This exhibition leads the audience into the micro environment of the human body through an immersive light and shadow experience. Through various light and shadow effects, the audience is immersed in the human blood and lymphatic tissue, witnessing the occurrence of various types of lymphoma caused by B cell mutations, as well as the various impacts of lymphoma on the human body. "The treatment and life of lymphoma patients after falling ill is actually like a journey of exploring the unknown in the universe." Gu Hongfei, the founder of Lymphoma Home, said, "As a science student, I have always been full of longing for the vast universe. I am glad that we have the opportunity to host this exhibition, to educate the public about lymphoma disease knowledge with a new perspective and language, and to establish a standardized diagnosis and treatment concept." As a former lymphoma patient, he also witnessed the continuous change of lymphoma treatment plans, and countless patients benefited from it. Standing at a new starting point in their recovered life, they can also look up at the starry sky, reach out to pick up the once unreachable stars, and bring hope and healing light to more people.
Collaborating with lymphoma patients to achieve cure
With the introduction of innovative drugs and the iteration of standardized treatment plans in recent years, the overall survival status of lymphoma patients in China has significantly improved, and lymphoma has become one of the tumors with high control and cure rates. In this exhibition, an immersive display of the history of human struggle against lymphoma was also systematically presented, allowing the audience to experience firsthand how different treatment methods, including radiotherapy, chemotherapy, targeting, cell therapy, and immunity, can inhibit the growth of lymphoma.
![Exploring "Curable Hematological Diseases": The First Immersive Lymphoma Light and Shadow Science Exhibition Opened in Shanghai](https://a5qu.com/upload/images/ab8c1325877be59f4bdd92722453ecc3.jpeg)
According to Ma Jun, the director of Harbin Institute of Hematology and Oncology, humans have been exploring effective treatment options for lymphoma, from the earliest nitrogen mustard era to the emergence of the first biological monoclonal antibody CD20, to antibody conjugates like CD79b, as well as recently developed bispecific antibodies that can simultaneously target CD20 and CD3, and even the application of technologies such as bone marrow transplantation and cell therapy in the later stage. More and more innovative drugs and cell therapy are making clinical cure possible for lymphoma patients.
In clinical practice, complete remission can be achieved when all tumors in the patient's body disappear; Patients who have achieved complete remission for 5 years can be considered clinically cured of lymphoma. Wang Li, Chief Physician of the Hematology Department at Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine, introduced that currently, the cure rate of lymphoma in developed areas such as Beijing, Shanghai, and Guangzhou in China can reach 60% to 70%. However, in some areas of the central and western regions, the treatment effectiveness rate is relatively low. Therefore, through the promotion of standardized guidelines, we hope to make the treatment more homogeneous nationwide.
"In recent years, China has vigorously built a multi-level medical security system, and many innovative drugs have entered the national medical insurance drug catalog through national medical insurance negotiations shortly after being approved. For example, Otuzumab entered the medical insurance in the year of approval, greatly reducing the burden on patients. At the same time, many innovative drugs are also continuously improving the accessibility of innovative drugs to lymphoma patients through social and commercial insurance, welfare insurance, and medical charity projects." said Wu Depei from the First Affiliated Hospital of Suzhou University.
Bai Ou from the Norman Bethune First Hospital of Jilin University also talked about the first diagnosis and treatment of lymphoma patients in China, as well as the subsequent treatment often in different medical institutions or even cities. Therefore, building a lymphoma grading diagnosis and treatment system and helping lymphoma patients achieve referral and treatment is crucial to ensure standardized treatment for lymphoma patients. "At present, we are pleased to see that some hospitals with higher levels of lymphoma treatment have begun to explore a case management system for lymphoma patients. They are not only responsible for educating lymphoma patients in the hospital, but also exploring ways to help patients connect with post discharge follow-up and referral work."
![Exploring "Curable Hematological Diseases": The First Immersive Lymphoma Light and Shadow Science Exhibition Opened in Shanghai](https://a5qu.com/upload/images/b1290cae06ff69b5416121567e0a97b6.jpeg)
As a joint supporter of this science popularization exhibition, Bian Xin, President of Roche Pharmaceuticals China, said, "In the past two years, innovative lymphoma products have continuously entered China, benefiting domestic patients. We will actively explore and build a comprehensive care system for lymphoma patients with all sectors of society, and strive to help more lymphoma patients achieve the ultimate goal of cure."